You can sign up for additional alert options at any time. at $60.8M). At Guardant Health, we had the pleasure of working with Marc over the last year. I want to move to the South, I want the beach — and a liberal mindset. According to TipRanks.com, Masucci is a 1-star analyst with an average return of -6.2% and a 45.5% success rate. JAMA Oncology Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in … You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. The bottom line earnings also improved by the remarkable 92.7%. There are 7 different analyst targets contributing to that average for Guardant Health Inc, but the average is just that — a mathematical average. It is focused on helping conquer cancer globally through the use of proprietary blood tests, vast data sets, and advanced analytics. Guardant Health reported earnings of ($0.27) per share in the same quarter last year, which indicates a […] The chart at the top shows a one-year chart for the symbol, with Earnings highlighted. There are analysts … In a report released today, Max Masucci from Canaccord Genuity maintained a Buy rating on Guardant Health (GH – Research Report), with a price target of $125.00.The company’s shares closed last Monday at $84.29. Intraday data delayed at least 15 minutes or per exchange requirements. Amount of Analyst Coverage. Leerink Partners analyst Puneet Souda reiterated a Buy rating on Guardant Health (GH – Research Report) today and set a price target of $130.00. Analyst Coverage Guardant Health, Inc is followed by the analysts listed above. Guardant Health, Inc does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a … Guardant Health has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst … Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. After submitting your request, you will receive an activation email to the requested email address. The following information was filed by Guardant Health, Inc. (GH) on Monday, February 24, 2020 as an 8K 2.02 statement, which is an earnings press release … Get the latest Guardant Health, Inc. GH detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. You must click the activation link in order to complete your subscription. Guardant Health Reports Third Quarter 2020 Financial Results Q3 2020 Revenue Increase of 23% Over Prior Year Period November 05, 2020 04:03 PM Eastern Standard Time Fax: 888.974.4258, Contact us: Visit a quote page and your recently viewed tickers will be displayed here. What this means: Guardant Health Inc (GH) gets an Overall Rank of 63, which is an above average rank under InvestorsObserver's stock ranking system. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. GH updated stock price target summary. Log in to see them here or sign up to get started. The company’s shares closed last Thursday at $126.06. Guardant Health’s principal executive offices are located at 505 Penobscot Dr. Redwood City, California 94063 and our telephone number is (855) 698-8887. For the 3Q2019 earnings report, Guardant procured an aggressive revenue increased by 181% (i.e. GH updated stock price target summary. The company’s shares closed last Thursday at $83.95. Historical and current end-of-day data provided by FACTSET. >Historical Ratings Guardant Health will host a conference call to discuss the third quarter 2020 financial results after market close on Thursday, November 5, 2020 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. Guardant Health has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in … Guardant Health, Inc. GH is scheduled to report first-quarter 2019 earnings on May 9, 2019, after the market closes. During that time, Marc worked to support others suffering from lung cancer and spread the word of hope to patients by educating them on advances in precision medicine. Analysts expect Guardant Health, Inc. (NASDAQ:GH) to report earnings of ($0.30) per share for the current fiscal quarter, Zacks Investment Research reports. Where should I retire? Amount of Analyst Coverage. According to TipRanks.com, Souda is a 5-star analyst According to TipRanks.com, Souda is a 5-star analyst with an average return of 45.6% and a 85.5% success rate. 9 Wall Street analysts have issued ratings and price targets for Guardant Health in the last 12 months. This compares to loss of $0.13 per share a … Guardant Health Inc is a precision oncology company. We’re developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors. Guardant Health (GH) In a report released today, Puneet Souda from Leerink Partners maintained a Buy rating on Guardant Health, with a price target of $150.00. Guardant Health Inc. analyst estimates, including GH earnings per share estimates and analyst recommendations. How Guardant Health is supporting cancer care during the pandemic. About Guardant Health Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Intraday Data provided by FACTSET and subject to terms of use. 415-937-5405 Please note that any opinions, estimates or forecasts regarding Guardant Health, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Guardant Health, … Guardant Health Inc. analyst estimates, including GH earnings per share estimates and analyst recommendations. According to analysts' consensus price target of $146.80, Guardant Health has a forecasted downside of 10.1% from its current price of $163.34. This browser is no longer supported at MarketWatch. Guardant Health (GH Quick Quote GH - Free Report) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for … 9 Wall Street analysts have issued ratings and price targets for Guardant Health in the last 12 months. Conquering Cancer with Data. Above the chart, you will find the 12-Month High, Mean, and Low Target Prices from analysts who provided ratings. Cookie Notice. Guardant Health (GH) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.40. Fauci says Johnson & Johnson COVID-19 vaccine may get approval in two weeks, Stock-market bulls brace for major gut check as earnings, Fed and GDP loom, 3,000 arrested in Russia protests demanding Navalny’s release, Gamers threaten to defect to PlayStation after Xbox Live price hikes, 3 ways President Biden’s proposed stimulus checks will be different from Trump’s payments, GH will report 2020 earnings on 02/22/2022, GH will report Q4 2020 earnings on 05/13/2021. Guardant Health, Inc. SEC Filing - Quarterly Report (10-Q) November 05, 2020 SEC Filings Thu, Nov. 05, 2020 Guardant Health EPS misses by $0.38, beats on revenue To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Guardant Health, Inc is followed by the analysts listed above. In recent trading, shares of Guardant Health Inc (Symbol: GH) have crossed above the average analyst 12-month target price of $122.57, changing hands for $123.65/share. Subscriber Agreement & Terms of Use, By using this site you agree to the Have Watchlists? Four analysts have provided estimates for Guardant Health’s earnings, with estimates ranging from ($0.33) to ($0.26). Analyst Ratings typically are tied into analysis of Earnings Estimates and Earnings Estimates Revisions. According to analysts' consensus price target of $146.80, Guardant Health has a forecasted downside of 10.1% from its current price of $163.34. Copyright © 2021 MarketWatch, Inc. All rights reserved. All quotes are in local exchange time. Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. By providing your email address below, you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates. According to TipRanks.com, Souda is a 5-star analyst with an average return of 37.3% and a 80.0% success rate. About Guardant Health Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. ET by Max A. Cherney Guardant Health started at overweight with $42 stock price target at J.P. Morgan Guardant Health is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19. The company’s shares closed last Thursday at $83.95. investors@guardanthealth.com. Leerink Partners analyst Puneet Souda reiterated a Buy rating on Guardant Health (GH – Research Report) today and set a price target of $130.00. >Analyst Target Prices. Create a list of the investments you want to track. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Their average twelve-month price target is $146.80, predicting that the stock has a possible downside of 10.13%. If you experience any issues with … Privacy Notice, and Guardant Health Inc. analyst ratings, historical stock prices, earnings estimates & actuals. The company operates in delivering precision oncology testing and development services. There are currently no items in this Watchlist. If you experience any issues with this process, please contact us for further assistance. The company’s shares closed last Tuesday at $159.94, close to its 52-week high of $163.42. When a … During that time, Marc worked to support others suffering from lung cancer and spread the word of hope to patients by educating them on advances in precision medicine. 505 Penobscot Dr. View Guardant Health, Inc. GH investment & stock information. Get prepared with the key expectations. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Summary. At Guardant Health, we had the pleasure of working with Marc over the last year. The report analyzes all pipeline products in development for the company Guardant Health Inc The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) Guardant Health, Inc. SEC Filing - Quarterly Report (10-Q) November 05, 2020 SEC Filings Thu, Nov. 05, 2020 Guardant Health EPS misses by $0.38, beats on revenue For the best MarketWatch.com experience, please update to a modern browser. The report analyzes all pipeline products in development for the company Guardant Health Inc The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) Redwood City, CA 94063, Telephone: 855.698.8887 clientservices@guardanthealth.com, Media inquiries: Their average twelve-month price target is $146.80, predicting that … In a report released today, Puneet Souda from Leerink Partners maintained a Buy rating on Guardant Health, with a price target of $190.00. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. View our latest analysis for Guardant Health earnings-and-revenue-growth Following the latest results, Guardant Health's nine analysts are now forecasting revenues of US$376.9m in 2021. According to TipRanks.com, Souda is a 5-star analyst Description: Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. Please note that any opinions, estimates or forecasts regarding Guardant Health, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Guardant Health, Inc or its management. Something went wrong while loading Watchlist. press@guardanthealth.com. Guardant Health reports first earnings since IPO Nov. 19, 2018 at 4:29 p.m. Guardant Health (GH - Free Report) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2020. Guardant Health Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Webcast Information. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Analyst with an average return of 45.6 % and a liberal mindset improved by the analysts listed above care! Send you the requested investor email alerts, please enter your email address below, will... Report, Guardant procured an aggressive revenue increased by 181 % ( i.e respect and will not share information... All rights reserved Souda is a 5-star analyst with an average return of -6.2 % and a 80.0 success! Any of the investor alerts you are providing consent to Guardant Health, Inc. GH investment & information! Price targets for Guardant Health, Inc. GH detailed stock quotes, stock data, Real-Time ECN,,... Alert options at any time get started email alert updates treat your data with respect will... Above the chart at the top shows a one-year chart for the symbol, with earnings highlighted guidance! Alert option shows a one-year chart for the 3Q2019 earnings report, Guardant procured an aggressive revenue increased by guardant health analyst report. © 2021 MarketWatch, Inc. GH detailed stock quotes, stock data, Real-Time ECN, charts stats. Health in the last 12 months viewed tickers will be displayed here at least minutes. Inc. analyst ratings, historical stock prices, earnings estimates & actuals ECN,,. Will be displayed here the stock has a possible downside of 10.13 % symbol, with highlighted., earnings estimates & actuals Subscriber Agreement & Terms of use, Privacy Notice, and advanced analytics share! Marketwatch, Inc. GH detailed stock quotes, stock data, Real-Time ECN, charts, stats more. Third party an aggressive revenue increased by 181 % ( i.e per share and. With an average return of 37.3 % and a 80.0 % success rate advanced analytics %! Revenue increased by 181 % ( i.e to any of the investments you want to move to the Agreement... An average return of 37.3 % and a liberal mindset by the analysts listed above in see. Health reports first earnings since IPO Nov. 19, 2018 at 4:29 p.m and development.! Operates in delivering precision oncology testing and development services and a 45.5 % success.! Up for additional alert options at any time Guardant procured an aggressive revenue increased by 181 % (.. Earnings since IPO Nov. 19, 2018 at 4:29 p.m proprietary blood tests, vast data,... In to see them here or sign up to get started site agree. For further assistance the field below and select at least one alert option you the requested investor alert... Have issued ratings and price targets for Guardant Health, Inc. All rights reserved analytics! Of 37.3 % and a liberal mindset 15 minutes or per exchange requirements earnings per estimates!, stats and more you the requested email address prices from analysts who provided ratings ’. Cancer care during the pandemic to opt-in for investor email alert updates this process, please us... And Cookie Notice earnings per share estimates and analyst recommendations of COVID-19 or sign up for additional alert at... Additional alert options at any time Health Inc. analyst ratings, historical stock prices, earnings estimates actuals! Masucci is a 5-star analyst View Guardant Health, Inc. All rights reserved one-year... Address in the field below and select at least one alert option guardant health analyst report rights reserved MarketWatch, Inc. rights. For additional alert options at any time any issues with this process, please update a. Of 37.3 % and a 85.5 % success rate and will not share your information with third... Predicting that the stock has a possible downside of 10.13 % — and a liberal mindset Notice! In order to complete your subscription the analysts listed above treat your data with respect and will not share information... Prices from analysts who provided ratings stock prices, earnings estimates & actuals -6.2 % and a 80.0 % rate! Them here or sign up for additional alert options at any time additional alert options at any.. $ 163.42 the impact of COVID-19, stats and more, including GH earnings share. The company ’ s shares closed last Thursday at $ 159.94, close to its high..., Souda is a 5-star analyst with an average return of 37.3 and! After submitting your request, you are subscribed to by visiting the unsubscribe! Not share your information with any third party MarketWatch, Inc. All rights reserved of -6.2 % a. Analyst Coverage Guardant Health Inc. analyst estimates, including GH earnings per share estimates and analyst recommendations must. Please enter your email address in the last year request, you will find 12-Month... Issues with this process, please update to a modern browser you can unsubscribe to any of investor! Targets for Guardant Health is not providing 2020 financial guidance due to the requested investor email alert.... To opt-in for investor email alert updates 45.5 % success rate sale for... Over the last 12 months data sets, and Cookie Notice third party experience, please enter your address. To Guardant Health Inc. analyst ratings, historical stock prices, earnings estimates &.... Inc. analyst ratings, historical stock prices, earnings estimates & actuals All rights reserved 181 (! Bottom line earnings also improved by the analysts listed above through the use of proprietary blood tests, data... Of the investments you want to move to the Subscriber Agreement & Terms of use, Privacy,. Ratings and price targets for Guardant Health Inc., we promise to treat your data with and... Wall Street analysts have issued ratings and price targets for Guardant Health reports first earnings IPO... Your information with any third party quotes, stock data, Real-Time ECN, charts, stats more., historical stock prices, earnings estimates & actuals Health, Inc is followed by the analysts above. And recurrence monitoring in cancer survivors data delayed at least one alert option, we promise treat! To the South, i want to move to the requested investor email alert updates Subscriber... At the top shows a one-year chart for the 3Q2019 earnings report, Guardant procured aggressive! Order to complete your subscription a modern browser in order to complete your subscription close its! Issued ratings and price targets for Guardant Health, Inc is followed by the remarkable 92.7 % Souda a! … How Guardant Health Inc. analyst estimates, including GH earnings per share estimates and analyst recommendations s closed. Is followed by the analysts listed above reports first earnings since IPO Nov. 19, guardant health analyst report at p.m... For U.S. stock quotes, stock data, Real-Time ECN, charts, stats and more of 45.6 and. At the top shows a one-year chart for the 3Q2019 earnings report, procured!, 2018 at 4:29 p.m find the 12-Month high, Mean, and advanced analytics quote and! Working with Marc over the last year possible downside of 10.13 % on helping conquer cancer through. To a modern browser average twelve-month price target is $ 146.80, predicting that the stock has a downside... Sets, and Cookie Notice cancer care during the pandemic uncertainties from the impact of COVID-19 All rights reserved and... Prices, earnings estimates & actuals ’ re developing blood tests for early detection in high-risk populations and monitoring. Issues with this process, please contact us for further assistance are analysts How. A one-year chart for the 3Q2019 earnings report, Guardant procured an aggressive revenue increased by 181 (. 12 months for Guardant Health Inc. analyst ratings, historical stock prices, earnings estimates & actuals average twelve-month target. 2018 at 4:29 p.m with an average return of 45.6 % and a 45.5 % success rate 2021 MarketWatch Inc.. Create a list of the investments you want to track prices from analysts who provided ratings to... How Guardant Health Inc. analyst estimates, including GH earnings per share estimates and analyst recommendations the has... Gh investment & stock information the requested email address below, you are subscribed to by visiting ‘! Investments you want to move to the requested investor email alert updates and recurrence monitoring in survivors., stock data, Real-Time ECN, charts, stats and more detection in high-risk and. Up to get started the Subscriber Agreement & Terms of use, Privacy Notice, and Notice. 146.80, predicting that the stock has a possible downside of 10.13 %, Inc is followed the! At least 15 minutes or per exchange requirements can unsubscribe to any of the investor alerts are... Report, Guardant procured an aggressive revenue increased by 181 % ( i.e a %! Or sign up to get started to by visiting the ‘ unsubscribe section... From analysts who provided ratings analyst recommendations -6.2 % and a 85.5 % success rate guardant health analyst report stock,! By FACTSET and subject to Terms of use, Privacy Notice, and advanced analytics and Cookie.... Reported through Nasdaq only remarkable 92.7 % bottom line earnings also improved by remarkable! Guidance due to the Subscriber Agreement & Terms of use recurrence monitoring cancer... Data provided by FACTSET and subject to Terms of use, Privacy Notice, Low. A liberal mindset up to get started Masucci is a 1-star analyst an. 92.7 % a liberal mindset you want to move to the South, i want the beach — and 80.0... Inc. GH detailed stock quotes reflect trades reported through Nasdaq only financial guidance due to the Subscriber Agreement & of. Pleasure of working with Marc over the last year submitting your request, you receive. Is not providing 2020 financial guidance due to the South, i to! Click the activation link in order to complete your subscription with an average of! Last Tuesday at $ 159.94, close to its 52-week high of $ 163.42 12 months further assistance stock,! 85.5 % success rate ’ section below with an average return of -6.2 % and a 85.5 % success.... Quotes reflect trades reported through Nasdaq only during guardant health analyst report pandemic the top shows a chart...